SCHEMBL2925938

SCHEMBL2925938

C[C@@H]1CCC[C@H](C)N1Cc1ccc2cc(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)ccc2n1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.72
HTR2C P28335 7/20 0.72
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
HTR1A P08908 3/20 0.44
HTR1B P28222 3/20 0.44
HTR1F P30939 3/20 0.44
PTPN1 P18031 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ADORA2A P29274 1/20 0.43
HTR1D P28221 2/20 0.42
POLB P06746 1/20 0.42
MLLT1 Q03111 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2926593 0.96 MCHR1 (0.71) MCHR1HTR2CMAPTSMN1; SMN2KDM4E
SCHEMBL2928051 0.92 MCHR1 (0.59) MCHR1HTR2CNPC1RAB9AMLLT1
SCHEMBL2925595 0.92 MCHR1 (0.59) MCHR1HTR2CSMN1; SMN2KDM4EMEN1
SCHEMBL13177410 0.91 MCHR1 (0.58) MCHR1HTR2CSMN1; SMN2MEN1ALDH1A1
SCHEMBL2926363 0.91 MCHR1 (0.58) MCHR1HTR2CSMN1; SMN2MEN1ALDH1A1
SCHEMBL2926531 0.89 MCHR1 (0.57) MCHR1HTR2CMAPTALDH1A1LMNA
SCHEMBL2921993 0.88 MCHR1 (0.59) MCHR1HTR2CMAPTSMN1; SMN2MEN1
SCHEMBL2925011 0.87 MCHR1 (0.58) MCHR1HTR2CMAPTSMN1; SMN2MEN1
SCHEMBL13177221 0.84 MCHR1 (0.51) MCHR1HTR2CSMN1; SMN2MEN1ALDH1A1
SCHEMBL2927594 0.84 MCHR1 (1.00) MCHR1HTR2CMAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885HTR2C 107/4885MAPT 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.